A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease

This study has been completed.
Sponsor:
Information provided by:
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00243945
First received: October 24, 2005
Last updated: August 27, 2014
Last verified: September 2009
  Purpose

The objective of this trial is to assess the effect of rotigotine (SPM 962) on the control of early morning motor impairment and sleep disorders in subjects with idiopathic PD.

Subjects who meet eligibility criteria will begin treatment with rotigotine transdermal patches. Trial medication will be titrated to an optimal daily dose, or to the maximal dose. Following a Titration period of up to 8 weeks, subjects will be maintained on the optimal or maximal dose for 4 weeks. After the Maintenance period, subjects will have the option to enter into an open-label extension study.

The first subject was enrolled in December 2004. The last subject was enrolled in April 2005 and the last subject visit was conducted in July 2005. This study is now closed


Condition Intervention Phase
IDIOPATHIC PARKINSON'S DISEASE
Drug: Rotigotine
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3b, Open-Label, Multicenter, Multinational Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders in Patients With Idiopathic Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Motor performance; Sleep disorders; Clinical Global Impression; Patient Global Impression; Safety & Tolerability

Enrollment: 58
Study Start Date: December 2004
Study Completion Date: July 2005
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Idiopathic Parkinson's disease

Exclusion Criteria:

  • Subject has previously participated in a trial with rotigotine.
  • Subject has participated in another trial of an investigational drug within the last 28 days or is currently participating in another trial of an investigational drug.
  • Subject discontinued from previous therapy with a dopamine agonist after an adequate length of treatment at an adequate dose due to lack of efficacy as assessed by the investigator.
  • Subject has had prior therapy with a dopamine agonist within 28 days prior to Baseline.
  • Subject is receiving therapy with controlled-release levodopa within 28 days prior to baseline or is receiving therapy with tolcapone.
  • Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Visit 2: alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (including atypical), monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or amphetamine.
  • Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the 6 months prior to baseline.
  • Subject has atypical Parkinsonian syndromes (including drug-induced Parkinsonian syndromes).
  • Subject has a history of atopic eczema and/or active skin disease, such as atopic eczema.
  • Presence of dementia, active psychosis, or hallucinations (not due to antiparkinsonian medication).
  • Subject is receiving CNS therapy (eg, sedatives, hypnotics, selective serotonin reuptake inhibitors [SSRIs], anxiolytics, other sleep-modifying medication) unless dose has been stable daily for at least 28 days prior to baseline and is likely to remain stable for the duration of the trial.
  • Subject has a history of seizures or stroke within 1 year, or a history of myocardial infarction within the last 6 months prior to enrollment.
  • Subject has neoplastic disease requiring therapy within 12 months prior to enrollment.
  • Presence of clinically relevant hepatic dysfunction.
  • Presence of clinically relevant renal dysfunction.
  • Evidence of clinically relevant cardiovascular disorders.
  • Subject has a QTcB interval of ³500msec at Screening or Baseline (Visit 1 or 2; repeated measurements within 1 hour).
  • Subject has a history of chronic alcohol or drug abuse within the last 6 months.
  • Subject has clinically significant laboratory results that, in the opinion of the investigator, would make the subject unsuitable for entry into the trial.
  • Subject is pregnant or nursing, or is of child bearing potential but (i) not surgically sterile, or, (ii) not using adequate birth control methods (including at least one barrier method) or, (iii) not sexually abstinent, or (iv) subject is not at least two years post menopausal.
  • Subject has any medical or psychiatric condition that, in the opinion of the investigator, can jeopardize or would compromise the subject's ability to participate in this trial.
  • Subject has a known hypersensitivity to any components of the trial medication stated in this protocol.
  • Subject has a previous diagnosis of narcolepsy, sleep apnea syndrome, rapid eye movement (REM) behavior disorder, restless legs syndrome, or periodic limb movement disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00243945

Locations
Germany
Schwarz
Monheim, Germany
Sponsors and Collaborators
UCB Pharma
Investigators
Study Director: UCB Clinical Trial Call Center UCB Pharma
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00243945     History of Changes
Other Study ID Numbers: SP826, 2004-002598-21
Study First Received: October 24, 2005
Last Updated: August 27, 2014
Health Authority: United Kingdom: National Health Service

Additional relevant MeSH terms:
Parkinson Disease
Sleep Disorders
Parasomnias
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Mental Disorders
N 0437
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 22, 2014